Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor

被引:1
|
作者
Rakotoambinina, B
Médioni, J
Rabian, C
Jubault, V
Jais, JP
Viard, JP
机构
[1] Hop Necker Enfants Malad, Serv Immunol Clin, F-75743 Paris 15, France
[2] Hop Necker Enfants Malad, Dept Biostat, F-75743 Paris 15, France
关键词
lipodystrophy; protease inhibitors; nucleoside analogs; hyperlipidemia; HIV infection;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To assess the frequency and features of lipodystrophic syndromes in HIV-1-infected patients receiving highly active antiretroviral therapy (HAART) with a protease inhibitor (PI), and examine whether clinical and biologic abnormalities are always associated in these conditions. Methods: Retrospective-prospective single-center observational study of 175 patients. Comparisons for continuous variables by t-test and paired t-test, and Kaplan-Meier analysis of time to onset of lipodystrophy were performed. Results: In all, 51 patients (29%) had morphologic changes, after a mean HAART duration of 20.0 +/- 6.1 months, and were categorized into pure lipoatrophy (n = 16), mixed syndrome (truncal fat accumulation and face or limb lipoatrophy) (n = 30) or pure truncal fat accumulation (In = 5). Because of the small number, the latter group was not analyzed statistically. No differences were found among patients with lipoatrophy, mixed syndrome, or no lipodystrophy, in terms of gender, CD4 count, and HIV RNA plasma load at time of HAART initiation, nor in response to treatment. Patients with a mixed syndrome were older. Patients with lipoatrophy had longer duration of HIV disease, pre-HAART exposure to nucleoside analog therapy, and HAART. Baseline and pre-HAART fasting triglyceride levels were higher in patients who developed lipoatrophy, whereas weight and fasting cholesterol were higher in patients who developed a mixed syndrome. After 12 and 24 months on HAART, triglycerides and cholesterol rose significantly in all patients, independently of lipodystrophy, whereas these parameters were not increased during nucleoside analog therapy. Conclusions: Nucleoside analog exposure appears as a risk factor for lipoatrophy. Age and nutritional status (reflected by baseline weight, triglycerides and cholesterol) may influence the evolution to lipoatrophy or a mixed syndrome. Hyperlipidemia is observed in the absence of lipodystrophy and depends on PI exposure.
引用
收藏
页码:443 / 449
页数:7
相关论文
共 50 条
  • [21] Interruption of prophylaxis for major opportunistic infections in HIV-infected patients receiving triple combination antiretroviral therapy
    Jubault, V
    Pacanowski, J
    Rabian, C
    Viard, JP
    ANNALES DE MEDECINE INTERNE, 2000, 151 (03): : 163 - 168
  • [22] Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients
    Burgos, Joaquin
    Crespo, Manuel
    Falco, Vicenc
    Curran, Adria
    Navarro, Jordi
    Imaz, Arkaitz
    Domingo, Pere
    Podzamczer, Daniel
    Gracia Mateo, Ma
    Villar, Sara
    Van den Eynde, Eva
    Ribera, Esteve
    Pahissa, Albert
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (10) : 2479 - 2486
  • [23] Improved Survival of HIV-1-Infected Patients with Progressive Multifocal Leukoencephalopathy Receiving Early 5-Drug Combination Antiretroviral Therapy
    Gasnault, Jacques
    Costagliola, Dominique
    Hendel-Chavez, Houria
    Dulioust, Anne
    Pakianather, Sophie
    Mazet, Anne-Aurelie
    de Herve, Marie-Ghislaine de Goer
    Lancar, Remi
    Lascaux, Anne-Sophie
    Porte, Lydie
    Delfraissy, Jean-Francois
    Taoufik, Yassine
    PLOS ONE, 2011, 6 (06):
  • [24] A prospective cohort study on the risk of lipodystrophy in HIV-1-infected patients treated with highly active antiretroviral therapy not containing protease inhibitors
    Martinez, E
    Bailey, L
    Milinkovic, A
    Blanco, JL
    Lonca, M
    Laguno, M
    Leon, A
    Mallolas, J
    Phillips, AN
    Gatell, JM
    ANTIVIRAL THERAPY, 2003, 8 (04) : L80 - L80
  • [25] Profiling of Inflammatory Proteins in Plasma of HIV-1-Infected Children Receiving Antiretroviral Therapy
    Lemma, Mahlet
    Petkov, Stefan
    Bekele, Yonas
    Petros, Beyene
    Howe, Rawleigh
    Chiodi, Francesca
    PROTEOMES, 2020, 8 (03) : 1 - 14
  • [26] Viral excretion in cervicovaginal secretions of HIV-1-infected women receiving antiretroviral therapy
    Debiaggi, M
    Zara, F
    Spinillo, A
    De Santolo, A
    Maserati, R
    Bruno, R
    Sacchi, P
    Achilli, G
    Pistorio, A
    Romero, E
    Filice, G
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2001, 20 (02) : 91 - +
  • [27] Viral Excretion in Cervicovaginal Secretions of HIV-1-Infected Women Receiving Antiretroviral Therapy
    M. Debiaggi
    F. Zara
    A. Spinillo
    A. De Santolo
    R. Maserati
    R. Bruno
    P. Sacchi
    G. Achilli
    A. Pistorio
    E. Romero
    G. Filice
    European Journal of Clinical Microbiology and Infectious Diseases, 2001, 20 : 91 - 96
  • [28] Recurrent cerebrospinal fluid escape in an HIV-1-infected patient receiving antiretroviral therapy
    Martins, Joana
    Santos, Ernestina
    Salgado, Paula
    Maia, Luis
    Dias, Daniel
    Marta, Monica
    Franca, Margarida
    AIDS, 2016, 30 (07) : 1143 - 1144
  • [29] Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients
    Collins, Sean E.
    Grant, Philip M.
    Shafer, Robert W.
    DRUGS, 2016, 76 (01) : 75 - 98
  • [30] Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients
    Sean E. Collins
    Philip M. Grant
    Robert W. Shafer
    Drugs, 2016, 76 : 75 - 98